Protein
aggregation is an obstacle for the development of new biopharmaceuticals,
presenting challenges in shipping and storage of vital therapies.
Though a variety of materials and methods have been explored, the
need remains for a simple material that is biodegradable, nontoxic,
and highly efficient at stabilizing protein therapeutics. In this
work, we investigated zwitterionic polypeptides prepared using a rapid
and scalable polymerization technique and conjugated to a supramolecular
macrocycle host, cucurbit[7]uril, for the ability to inhibit aggregation
of model protein therapeutics insulin and calcitonin. The polypeptides
are based on the natural amino acid methionine, and zwitterion sulfonium
modifications were compared to analogous cationic and neutral structures.
Each polymer was end-modified with a single cucurbit[7]uril macrocycle
to afford supramolecular recognition and binding to terminal aromatic
amino acids on proteins. Only conjugates prepared from zwitterionic
structures of sufficient chain lengths were efficient inhibitors of
insulin aggregation and could also inhibit aggregation of calcitonin.
This polypeptide exhibited no cytotoxicity in human cells even at
concentrations that were five-fold of the intended therapeutic regime.
We explored treatment of the zwitterionic polypeptides with a panel
of natural proteases and found steady biodegradation as expected,
supporting eventual clearance when used as a protein formulation additive.